Maymetsi

Active Ingredient:: Metformin Hydrochloride, Sitagliptin
Origin:: EU

Maymetsi (Metformin Hydrochloride, Sitagliptin)

Q: What is Maymetsi used for?

Maymetsi is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet, exercise, and possibly other antidiabetic agents.

Q: How does Metformin Hydrochloride and Sitagliptin work?

Metformin lowers glucose production by the liver and enhances insulin sensitivity, while Sitagliptin blocks the DPP‑4 enzyme, raising incretin levels that stimulate insulin release and reduce glucagon, together achieving better glycaemic regulation.

Q: What is the usual dose of Maymetsi?

The appropriate dose of Maymetsi is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant therapies.

Q: Is Maymetsi safe during pregnancy or breastfeeding?

Safety of Maymetsi in pregnancy or lactation has not been established. Healthcare providers should evaluate the risk‑benefit profile and consider alternative treatments when treating pregnant or nursing individuals.

Q: How do I order Maymetsi from GNH India?

To request Maymetsi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Q: How does Maymetsi compare with other antidiabetic options?

Maymetsi combines two mechanisms—biguanide and DPP‑4 inhibition—offering complementary glucose‑lowering effects. Compared with monotherapy agents, the combination can achieve greater HbA1c reduction without the need for multiple separate pills, though individual patient response and tolerance vary.

Q: What are the storage and handling requirements for Maymetsi?

Maymetsi tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Q: How is Maymetsi administered?

Maymetsi is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water and follow any specific timing instructions provided by the healthcare professional.

Q: What are the most serious risks associated with Maymetsi?

The most serious risks include lactic acidosis from metformin, especially in patients with renal or hepatic impairment, and severe hypoglycaemia when used with insulin or sulfonylureas. Prompt medical attention is required if symptoms of these conditions appear.

Q: Who should not use Maymetsi?

Maymetsi is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and in patients with a history of lactic acidosis. It should also be used with caution in those with hepatic disease.

Metformin Hydrochloride and Sitagliptin, the active ingredient in Maymetsi, is a Biguanide and DPP‑4 inhibitor combination presented as a combination tablet for oral use. It treats type 2 diabetes mellitus in adults.
GNH India supplies Maymetsi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Maymetsi, a combination of metformin and sitagliptin, is indicated for management of type 2 diabetes mellitus.
Type 2 diabetes mellitus: improves overall glycaemic control when used with diet and exercise.
Inadequate control on metformin alone: provides additional glucose‑lowering effect.
Combination therapy with other antidiabetics: can be added to sulfonylureas, insulin or thiazolidinediones for enhanced control.

How It Works

Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby lowering fasting glucose levels. Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which results in increased endogenous incretin hormones (GLP‑1 and GIP). These incretins enhance glucose‑dependent insulin secretion and suppress glucagon release, contributing to improved post‑prandial glucose regulation.

Side Effects

Maymetsi may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

Nausea or upset stomach.
Diarrhoea or loose stools.
Abdominal discomfort or flatulence.
Headache or mild dizziness.

Serious or Rare Side Effects

Lactic acidosis, a potentially life‑threatening metabolic disturbance.
Severe hypoglycaemia, especially when combined with insulin or sulfonylureas.
Acute pancreatitis presenting with abdominal pain and elevated enzymes.
Allergic reactions such as rash, angio‑edema or anaphylaxis.

Precautions & Warnings

Before initiating Maymetsi, several safety considerations should be reviewed.

Renal function assessment: avoid or adjust dose in patients with impaired renal clearance.
Hepatic impairment: monitor liver enzymes and avoid in severe liver disease.
Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia.
Concomitant hypoglycaemic agents: monitor blood glucose to prevent severe lows.
Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m²).
Store at room temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Maymetsi can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

Intravenous iodinated contrast agents: may precipitate metformin‑associated lactic acidosis.
Strong CYP3A4 inhibitors (e.g., ketoconazole): increase sitagliptin exposure.
Insulin or sulfonylureas: heightened risk of hypoglycaemia.
Cimetidine: raises sitagliptin plasma levels.

Moderate Interactions (Monitor Closely)

Diuretics: may affect renal clearance of metformin.
ACE inhibitors or ARBs: combined effect on renal function.
Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential impact on kidney function.
Alcohol: can increase risk of lactic acidosis.

Frequently Asked Questions

Maymetsi is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet, exercise, and possibly other antidiabetic agents.

Metformin lowers glucose production by the liver and enhances insulin sensitivity, while Sitagliptin blocks the DPP‑4 enzyme, raising incretin levels that stimulate insulin release and reduce glucagon, together achieving better glycaemic regulation.

The appropriate dose of Maymetsi is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant therapies.

Safety of Maymetsi in pregnancy or lactation has not been established. Healthcare providers should evaluate the risk‑benefit profile and consider alternative treatments when treating pregnant or nursing individuals.

To request Maymetsi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Maymetsi combines two mechanisms—biguanide and DPP‑4 inhibition—offering complementary glucose‑lowering effects. Compared with monotherapy agents, the combination can achieve greater HbA1c reduction without the need for multiple separate pills, though individual patient response and tolerance vary.

Maymetsi tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Maymetsi is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water and follow any specific timing instructions provided by the healthcare professional.

The most serious risks include lactic acidosis from metformin, especially in patients with renal or hepatic impairment, and severe hypoglycaemia when used with insulin or sulfonylureas. Prompt medical attention is required if symptoms of these conditions appear.

Maymetsi is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and in patients with a history of lactic acidosis. It should also be used with caution in those with hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 01 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.